百洋医药：净利润增速下降主要是公司向创新战略转型

Core Viewpoint - The company is experiencing a decline in net profit growth due to its strategic shift towards innovation, which has led to increased expenses from hiring new personnel for innovative drug development and prior promotional costs [1] Group 1 - The company is transitioning towards an innovative strategy, which is impacting its financial performance [1] - Increased expenses are attributed to the recruitment of new personnel for innovative drug initiatives and prior promotional expenditures [1] - The sales channel for the company's product, Diqiao, is shifting towards online platforms [1] Group 2 - Future revenue structure is expected to improve as new business initiatives gradually ramp up [1]